سعر دروناديكس 400 مجم 10 أقراص 2022

Egyptian dronedarone 400 mg tablets (EVA Pharma) for atrial fibrillation rhythm management.

• Reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent AF (US Multaq labeling).Population: AdultsDailyMed / FDA — MULTAQ (dronedarone)

• Common: diarrhea, nausea, abdominal pain, vomiting, asthenia; also bradycardia, QT prolongation, rash, elevated creatinine (US Multaq).International label, same formulation · DailyMed / FDA — MULTAQ (dronedarone)

• Permanent AF; symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV; second- or third-degree AV block or sick sinus syndrome without pacemaker; bradycardia <50 bpm; concomitant strong CYP3A inhibitors; concomitant drugs prolonging QT / Class I or III antiarrhythmics; QTc Bazett ≥500 ms; severe hepatic impairment; pregnancy (US Multaq boxed/contraindications).International label, same formulation · DailyMed / FDA — MULTAQ (dronedarone)

• Boxed warning: increased risk of death, stroke, and heart failure in patients with decompensated HF or permanent AF. Monitor cardiac rhythm, hepatic function, and drug interactions (US Multaq).International label, same formulation · DailyMed / FDA — MULTAQ (dronedarone)

• Strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)MajorContraindicated: strong CYP3A inhibitors increase dronedarone exposure (US Multaq).DailyMed / FDA — MULTAQ (dronedarone)
• Drugs that prolong QT / Class I or III antiarrhythmicsMajorContraindicated with drugs that prolong the QT interval and with Class I or III antiarrhythmics (US Multaq).DailyMed / FDA — MULTAQ (dronedarone)

• May cause fetal harm; contraindicated in pregnancy (US Multaq labeling).International label, same formulation · DailyMed / FDA — MULTAQ (dronedarone)

• Dronedarone: Multichannel blocker (Na, K, Ca channels) with antiadrenergic activity; maintains sinus rhythm in paroxysmal/persistent AF.